LEADER 03233nam  2200649Ia 450 
001 9910457692103321
005 20200520144314.0
010   $a0-19-174025-X
010   $a0-19-960737-0
010   $a1-283-34833-0
010   $a9786613348333
010   $a0-19-157581-X
035   $a(CKB)2550000000064626
035   $a(EBL)797725
035   $a(OCoLC)763157034
035   $a(SSID)ssj0000555589
035   $a(PQKBManifestationID)12244098
035   $a(PQKBTitleCode)TC0000555589
035   $a(PQKBWorkID)10519626
035   $a(PQKB)10355720
035   $a(MiAaPQ)EBC797725
035   $a(StDuBDS)EDZ0000091506
035   $a(Au-PeEL)EBL797725
035   $a(CaPaEBR)ebr10511371
035   $a(CaONFJC)MIL334833
035   $a(EXLCZ)992550000000064626
100   $a20100924d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aSystemic treatment of prostate cancer$b[electronic resource] /$fedited by Alan Horwich
210   $aOxford ;$aNew York $cOxford University Press$d2010
215   $a1 online resource (102 p.)
225 1 $aOxford oncology library
300   $aDescription based upon print version of record.
311   $a0-19-956142-7 
320   $aIncludes bibliographical references and index.
327   $aContents; Preface; Symbols and abbreviations; Contributors; 1 Biological principles of hormone therapy; 2 PSA as a marker of progression and response in advanced prostate cancer; 3 Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer; 4 Systemic treatment of recurrence after local therapies; 5 First-line hormone therapy for metastatic prostate cancer; 6 Second- and third-line hormone therapies; 7 Chemotherapy for metastatic prostate cancer; 8 The role of bisphosphonates in the systemic treatment of prostate cancer; 9 Systemic isotope therapy of bone metastasis
327   $a10 Biological targets and new drug development for prostate cancerIndex; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Z
330   $aProstate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r
410  0$aOxford oncology library.
606   $aProstate$xCancer$xDiagnosis
606   $aProstate$xCancer$xTreatment
608   $aElectronic books.
615  0$aProstate$xCancer$xDiagnosis.
615  0$aProstate$xCancer$xTreatment.
676   $a616.9946306
701   $aHorwich$b Alan$0939780
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910457692103321
996   $aSystemic treatment of prostate cancer$92118828
997   $aUNINA